文献速递心脑血管急症消化、代谢与肾脏急症

阿司匹林降低中度心血管风险患者初始血管事件风险(ARRIVE):随机、双盲、安慰剂对照试验

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet · 2018-08-26
一句话结论在中度心血管风险人群中,阿司匹林100 mg每日一次未显著降低首次心血管复合终点(HR 0.96),但胃肠道出血风险约翻倍(HR 2.11)。

ARRIVE为在7个国家501个中心开展的随机、双盲、安慰剂对照试验,纳入无糖尿病且胃肠道出血或其他出血高风险被排除的、基于特定危险因素数量判定为中度的心血管风险人群(男性≥55岁、女性≥60岁),共12546例,随机接受肠溶阿司匹林100 mg每日一次或安慰剂。中位随访60个月,意向性分析显示主要疗效终点(心血管死亡、心肌梗死、不稳定型心绞痛、卒中或短暂性脑缺血发作的首次发生)在阿司匹林组269例(4.29%)与安慰剂组281例(4.48%)间无显著差异(HR 0.96;95%CI 0.81-1.13;p=0.6038)。胃肠道出血事件(多为轻度)阿司匹林组61例(0.97%)高于安慰剂组29例(0.46%)(HR 2.11;95%CI 1.36-3.28;p=0.0007)。作者指出实际事件率远低于预期,可能反映当代风险管理策略,使研究更代表低风险人群,因此阿司匹林在中度风险人群一级预防中的作用未能回答。

要点

  • 男性≥55岁、女性≥60岁且基于特定危险因素数量判定为中度的心血管风险人群,阿司匹林100 mg每日一次未显著降低主要心血管复合终点(4.29% vs 4.48%;HR 0.96;95%CI 0.81-1.13;p=0.6038)。
  • 同一人群中,阿司匹林组胃肠道出血事件(多为轻度)发生率为0.97%,安慰剂组为0.46%(HR 2.11;95%CI 1.36-3.28;p=0.0007)。
  • 严重不良事件总发生率两组相似(阿司匹林组20.19% vs 安慰剂组20.89%),总不良事件发生率亦相似(82.01% vs 81.72%)。
  • 治疗相关不良事件总发生率阿司匹林组16.75%高于安慰剂组13.54%(p<0.0001)。
  • 作者指出实际事件率远低于预期,研究更代表低风险人群,阿司匹林在中度风险人群一级预防中的作用未能回答。

适用人群与场景

  • 年龄:男性55岁及以上、女性60岁及以上。
  • 排除:胃肠道出血或其他出血高风险患者,以及糖尿病患者。

处置流程与药物剂量

  • 肠溶阿司匹林片100 mg,每日一次,口服;对照为安慰剂片,每日一次。

研究设计与关键结果

  • 研究类型:随机、双盲、安慰剂对照、多中心研究;在7个国家501个研究点开展;2007年7月5日至2016年11月15日纳入12546例,随机分配至阿司匹林组(n=6270)或安慰剂组(n=6276);中位随访60个月。
  • 主要疗效终点(心血管死亡、心肌梗死、不稳定型心绞痛、卒中或短暂性脑缺血发作的首次发生复合终点):阿司匹林组269例(4.29%)vs 安慰剂组281例(4.48%);HR 0.96;95%CI 0.81-1.13;p=0.6038,未达统计学显著。
  • 胃肠道出血事件(多为轻度):阿司匹林组61例(0.97%)vs 安慰剂组29例(0.46%);HR 2.11;95%CI 1.36-3.28;p=0.0007。
  • 严重不良事件总发生率:阿司匹林组1266例(20.19%)vs 安慰剂组1311例(20.89%)。
  • 总不良事件发生率:阿司匹林组5142例(82.01%)vs 安慰剂组5129例(81.72%)。
  • 治疗相关不良事件总发生率:阿司匹林组1050例(16.75%)vs 安慰剂组850例(13.54%);p<0.0001。
  • 意向性治疗人群死亡:共321例,阿司匹林组160例(2.55%)vs 安慰剂组161例(2.57%)。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照、多中心试验。
  • 局限:作者指出实际事件率远低于预期,可能反映当代风险管理策略,使研究更代表低风险人群,因此阿司匹林在中度风险人群一级预防中的作用未能回答;原文未报告其他局限性。

对床旁实践的改变

  • 在中度心血管风险且无糖尿病、无胃肠道出血或其他出血高风险的人群中,阿司匹林100 mg每日一次未显著降低首次心血管复合终点,胃肠道出血事件(多为轻度)发生率升高(0.97% vs 0.46%)。
  • 作者指出实际事件率远低于预期,研究更代表低风险人群,阿司匹林在中度风险人群一级预防中的作用未能回答;该结果与此前低风险一级预防研究中所观察到的阿司匹林效应一致。

指南或共识出处

  • ARRIVE试验(ClinicalTrials.gov注册号NCT00501059),Bayer资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event.

METHODS: ARRIVE is a randomised, double-blind, placebo-controlled, multicentre study done in seven countries. Eligible patients were aged 55 years (men) or 60 years (women) and older and had an average cardiovascular risk, deemed to be moderate on the basis of the number of specific risk factors. We excluded patients at high risk of gastrointestinal bleeding or other bleeding, or diabetes. Patients were randomly assigned (1:1) with a computer-generated randomisation code to receive enteric-coated aspirin tablets (100 mg) or placebo tablets, once daily. Patients, investigators, and others involved in treatment or data analysis were masked to treatment allocation. The primary efficacy endpoint was a composite outcome of time to first occurrence of cardiovascular death, myocardial infarction, unstable angina, stroke, or transient ischaemic attack. Safety endpoints were haemorrhagic events and incidence of other adverse events, and were analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00501059.

FINDINGS: Between July 5, 2007, and Nov 15, 2016, 12 546 patients were enrolled and randomly assigned to receive aspirin (n=6270) or placebo (n=6276) at 501 study sites. Median follow-up was 60 months. In the intention-to-treat analysis, the primary endpoint occurred in 269 (4·29%) patients in the aspirin group versus 281 (4·48%) patients in the placebo group (hazard ratio [HR] 0·96; 95% CI 0·81-1·13; p=0·6038). Gastrointestinal bleeding events (mostly mild) occurred in 61 (0·97%) patients in the aspirin group versus 29 (0·46%) in the placebo group (HR 2·11; 95% CI 1·36-3·28; p=0·0007). The overall incidence rate of serious adverse events was similar in both treatment groups (n=1266 [20·19%] in the aspirin group vs n=1311 [20·89%] in the placebo group. The overall incidence of adverse events was similar in both treatment groups (n=5142 [82·01%] vs n=5129 [81·72%] in the placebo group). The overall incidence of treatment-related adverse events was low (n=1050 [16·75%] vs n=850 [13·54%] in the placebo group; p<0·0001). There were 321 documented deaths in the intention-to-treat population (n=160 [2·55%] vs n=161 [2·57%] of 6276 patients in the placebo group).

INTERPRETATION: The event rate was much lower than expected, which is probably reflective of contemporary risk management strategies, making the study more representative of a low-risk population. The role of aspirin in primary prevention among patients at moderate risk could therefore not be addressed. Nonetheless, the findings with respect to aspirin's effects are consistent with those observed in the previously published low-risk primary prevention studies.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018. PMID: 30158069. doi:10.1016/S0140-6736(18)31924-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。